摘要
目的观察血清白细胞介素-10(IL-10)、血管内皮生长因子(VEGF)在非肌层浸润性膀胱癌(NMIBC)患者中的表达情况,并分析其对患者经尿道膀胱肿瘤电切术(TURBT)治疗预后的影响。方法选择2017年1月至2019年7月于郑州大学第一附属医院接受TURBT治疗的115例NMIBC患者为研究对象,患者术后均随访24个月,观察并记录患者随访期间疾病复发情况,将其作为预后观察指标分为复发组与未复发组,调查并记录患者基线资料及血清IL-10、VEGF水平,分析血清IL-10、VEGF水平对NMIBC患者TURBT治疗预后的影响。结果术后随访24个月,115例患者中预后不良(复发)27例,占23.48%(27/115);预后不良组患者血清IL-10、VEGF水平高于预后良好组患者,差异有统计学意义(P<0.05);经logistic回归分析,结果显示,血清IL-10、VEGF过表达是NMIBC患者TURBT治疗预后不良的影响因子(OR>1,P<0.05)。结论血清IL-10、VEGF过表达提示NMIBC患者TURBT治疗预后不良风险较大。
Objective To observe the expression of serum interleukin-10(IL-10)and vascular endothelial growth factor(VEGF)in patients with non-muscle-invasive bladder cancer(NMIBC),and to analyze their effect on the prognosis of patients with transurethral resection of bladder tumor(TURBT).Methods A total of 115 patients with NMIBC who received TURBT in the First Affiliated Hospital of Zhengzhou University from January 2017 to July 2019 were selected as the research subjects.The patients were followed up for 24 months after operation.The disease recurrence of patients during the follow-up period was observed and recorded as a prognostic observation index and divided into recurrence group and non recurrence group.The baseline data and the levels of serum IL-10 and VEGF of patients were investigated and recorded,the effect of serum IL-10 and VEGF levels on the prognosis of patients with NMIBC treated by TURBT was analyzed.Results After 24 months of follow-up,27 of 115 patients had poor prognosis(recurrence),accounting for 23.48%(27/115).The levels of serum IL-10 and VEGF in patients with poor prognosis were higher than those in the good prognosis(P<0.05).Logistic regression analysis showed that the overexpression of serum IL-10 and VEGF were the influencing factors of the poor prognosis in patients with NMIBC treated by TURBT(OR>1,P<0.05).Conclusion The overexpression of serum IL-10 and VEGF suggests that patients with NMIBC are at high risk of poor prognosis treated by TURBT.
作者
马秀君
顾朝辉
MA Xiujun;GU Chaohui(Department of Urology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2021年第29期5448-5450,共3页
Henan Medical Research
作者简介
通信作者:顾朝辉,E-mail:1342651839@qq.com。
